Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety Study of WILFACTIN Long-Term Prophylaxis in von Willebrand Disease
2005-001746-17Phase 4Completed
- Sponsor
- LFB Group
- Start
- Nov 2007
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of von Willebrand factor human in von Willebrand disease (VWD), sponsored by LFB Group. Primary endpoints: Clinical efficacy – prevention or reduction of spontaneous bleeding, Biological efficacy – VWF:RCo recovery at inclusion and 1 more. Started Nov 2007; status: completed.
02
Drugs
von Willebrand factor human
03
Conditions
von Willebrand disease (VWD)
Beyond the preview
Go deeper on 2005-001746-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001746-17.